CABA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
54.7M
+5.0%
52.1M
+18.5%
44.0M
+3.2%
42.6M
-8.5%
46.6M
R&D
47.1M
+6.1%
44.4M
+18.9%
37.4M
+3.2%
36.2M
-9.1%
39.8M
SG&A
7.6M
-0.4%
7.6M
+9.3%
6.9M
+8.2%
6.4M
-5.1%
6.8M
Operating Income
-54707000
-5.0%
-52105000
-18.5%
-43955000
-3.2%
-42611000
+8.5%
-46588000
EBITDA
-54360000
-5.1%
-51734000
-18.6%
-43618000
-3.2%
-42263000
+8.6%
-46243000
Net Income
-53053000
-4.0%
-51018000
-17.2%
-43515000
-3.8%
-41919000
+6.6%
-44866000
EPS (Basic)
$-0.28
+17.6%
$-0.34
+12.8%
$-0.39
+2.5%
$-0.40
+9.1%
$-0.44
EPS (Diluted)
$-0.28
+17.6%
$-0.34
+12.8%
$-0.39
+2.5%
$-0.40
+9.1%
$-0.44
Shares (Diluted)
186.8M
+23.6%
151.2M
+34.9%
112.0M
+7.0%
104.7M
+2.4%
102.3M
Cabaletta Bio (CABA) — Financials